Survey: FDA‑Cleared AI for Breast Cancer Underperforms Expectations

The briefing

A survey of Society of Breast Imaging members found that, while about half use FDA‑approved AI tools for detection, results often lag expectations. Only 35% reported lower recall rates versus 59% who had expected such improvements, with similar gaps across other metrics.